Ocugen CMO Huma Qamar departs; Mohamed Genead named acting interim CMO

Ocugen, Inc.

Huma Qamar separated from Ocugen as Chief Medical Officer effective May 8, 2026.
Mohamed Genead, M.D., appointed Acting/Interim Chief Medical Officer effective May 8, 2026.
No reason for departure or transition details were disclosed in the filing.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Huma Qamar

Chief Medical Officer

OCGN · Ocugen, Inc.

Effective: 2026-05-08
Filed: May 14, 2026, 4:31 PM ET

Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Huma Qamar departed as Chief Medical Officer at Ocugen, Inc..

Action: separated
Role: Chief Medical Officer

Exact text from the filing

Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer.

View on SEC.gov

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-061241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.